Literature DB >> 15588506

Hematopoietic cancer and angiogenesis.

Domenico Ribatti1, Claudio Scavelli, Aldo M Roccaro, Enrico Crivellato, Beatrice Nico, Angelo Vacca.   

Abstract

The growth of solid tumors is certainly angiogenesis dependent. However, the role of angiogenesis in the growth and survival of leukemias and other hematological malignancies has only been rendered evident since 1994 in a series of demonstrations showing that the progression of several forms is clearly related to their degree of angiogenesis. Here, we present an overview of the literature concerning the relationship between angiogenesis and disease progression in several hematological malignancies and the recent advances in antiangiogenesis in these diseases and we describe the most important active substances, preclinical and clinical data, and future perspectives.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15588506     DOI: 10.1089/scd.2004.13.484

Source DB:  PubMed          Journal:  Stem Cells Dev        ISSN: 1547-3287            Impact factor:   3.272


  11 in total

Review 1.  Targeting cyclooxygenase-2 in hematological malignancies: rationale and promise.

Authors:  M P Bernard; S Bancos; P J Sime; R P Phipps
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

2.  ANGPT2 promoter methylation is strongly associated with gene expression and prognosis in chronic lymphocytic leukemia.

Authors:  Silvia Martinelli; Meena Kanduri; Rossana Maffei; Stefania Fiorcari; Jenny Bulgarelli; Roberto Marasca; Richard Rosenquist
Journal:  Epigenetics       Date:  2013-05-14       Impact factor: 4.528

3.  Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium.

Authors:  Danelle F James; Lillian Werner; Jennifer R Brown; William G Wierda; Jacqueline C Barrientos; Januario E Castro; Andrew Greaves; Amy J Johnson; Laura Z Rassenti; Kanti R Rai; Donna Neuberg; Thomas J Kipps
Journal:  J Clin Oncol       Date:  2014-05-27       Impact factor: 44.544

4.  Implications of a simple mathematical model to cancer cell population dynamics.

Authors:  A L Garner; Y Y Lau; D W Jordan; M D Uhler; R M Gilgenbach
Journal:  Cell Prolif       Date:  2006-02       Impact factor: 6.831

5.  Novel therapies for aggressive B-cell lymphoma.

Authors:  Kenneth A Foon; Kenichi Takeshita; Pier L Zinzani
Journal:  Adv Hematol       Date:  2012-03-25

6.  Erythropoietin/erythropoietin receptor system is involved in angiogenesis in human neuroblastoma.

Authors:  D Ribatti; P L Poliani; V Longo; D Mangieri; B Nico; A Vacca
Journal:  Histopathology       Date:  2007-04       Impact factor: 5.087

7.  miR-363-5p regulates endothelial cell properties and their communication with hematopoietic precursor cells.

Authors:  Ana Costa; Joana Afonso; Catarina Osório; Ana L Gomes; Francisco Caiado; Joana Valente; Sandra I Aguiar; Francisco Pinto; Mário Ramirez; Sérgio Dias
Journal:  J Hematol Oncol       Date:  2013-11-21       Impact factor: 17.388

8.  Allium compounds, dipropyl and dimethyl thiosulfinates as antiproliferative and differentiating agents of human acute myeloid leukemia cell lines.

Authors:  Faten Merhi; Jacques Auger; Francine Rendu; Brigitte Bauvois
Journal:  Biologics       Date:  2008-12

9.  Clinical role of bone marrow angiogenesis in childhood acute lymphocytic leukemia.

Authors:  Chuhl Joo Lyu; Sun Young Rha; Sung Chul Won
Journal:  Yonsei Med J       Date:  2007-04-30       Impact factor: 2.759

10.  Polymorphisms in the estrogen receptor 1 and vitamin C and matrix metalloproteinase gene families are associated with susceptibility to lymphoma.

Authors:  Christine F Skibola; Paige M Bracci; Eran Halperin; Alexandra Nieters; Alan Hubbard; Randi A Paynter; Danica R Skibola; Luz Agana; Nikolaus Becker; Patrick Tressler; Matthew S Forrest; Sriram Sankararaman; Lucia Conde; Elizabeth A Holly; Martyn T Smith
Journal:  PLoS One       Date:  2008-06-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.